These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33952262)

  • 1. Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer.
    Feng Y; Wang D; Xiong L; Zhen G; Tan J
    Cancer Cell Int; 2021 May; 21(1):249. PubMed ID: 33952262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PAWR predicts prognosis of ovarian cancer.
    Tan J; Tao K; Zheng X; Liu D; Ma D; Gao Q
    Cancer Cell Int; 2020 Dec; 20(1):598. PubMed ID: 33317551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.
    Compadre AJ; van Biljon LN; Valentine MC; Llop-Guevara A; Graham E; Fashemi B; Herencia-Ropero A; Kotnik EN; Cooper I; Harrington SP; Kuroki LM; McCourt CK; Hagemann AR; Thaker PH; Mutch DG; Powell MA; Sun L; Mosammaparast N; Serra V; Zhao P; Lomonosova E; Khabele D; Mullen MM
    Clin Cancer Res; 2023 Jul; 29(13):2466-2479. PubMed ID: 37097615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
    Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
    J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Location of Mutation in
    Labidi-Galy SI; Olivier T; Rodrigues M; Ferraioli D; Derbel O; Bodmer A; Petignat P; Rak B; Chopin N; Tredan O; Heudel PE; Stuckelberger S; Meeus P; Meraldi P; Viassolo V; Ayme A; Chappuis PO; Stern MH; Houdayer C; Stoppa-Lyonnet D; Buisson A; Golmard L; Bonadona V; Ray-Coquard I
    Clin Cancer Res; 2018 Jan; 24(2):326-333. PubMed ID: 29084914
    [No Abstract]   [Full Text] [Related]  

  • 7. Comprehensive Analysis of CCAAT/Enhancer Binding Protein Family in Ovarian Cancer.
    Tan J; Wang D; Dong W; Nian L; Zhang F; Zhao H; Zhang J; Feng Y
    Cancer Inform; 2024; 23():11769351241275877. PubMed ID: 39238655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
    Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer.
    Qiao Y; Yu X; Zhou B; Zhang K; Huang J; Liao J
    Transl Oncol; 2022 Oct; 24():101497. PubMed ID: 35917645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
    Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
    Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients.
    Gachechiladze M; Škarda J; Kolek V; Grygárková I; Langová K; Bouchal J; Kolář Z; Baty F; Stahel R; Weder W; Soltermann A; Joerger M
    Lung Cancer; 2017 Mar; 105():31-38. PubMed ID: 28236982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
    Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
    Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
    Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E
    Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
    Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
    Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Relevance of Circulating miR-622 in Patients with Newly Diagnosed and Recurrent High-Grade Serous Ovarian Carcinoma.
    Vigneron N; Vernon M; Meryet-Figuière M; Lambert B; Briand M; Louis MH; Krieger S; Joly F; Lheureux S; Blanc-Fournier C; Gauduchon P; Poulain L; Denoyelle C
    Clin Chem; 2020 Feb; 66(2):352-362. PubMed ID: 32040573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
    Mukhopadhyay A; Elattar A; Cerbinskaite A; Wilkinson SJ; Drew Y; Kyle S; Los G; Hostomsky Z; Edmondson RJ; Curtin NJ
    Clin Cancer Res; 2010 Apr; 16(8):2344-51. PubMed ID: 20371688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
    Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.